PLAT and COVID-19: This has been attributed to variations in fibrinolytic factors such as PAI-1 (>2-fold), tPA (>1.6-fold), and thrombin activatable fibrinolysis inhibitor (TAFI) (>1.7-fold) in critically ill COVID-19 patients (122).